These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30012756)

  • 1. Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.
    Dale GE; Halabi A; Petersen-Sylla M; Wach A; Zwingelstein C
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment.
    Preston RA; Mamikonyan G; Mastim M; Garg D; Kemper CJ; Xu A; Yeole R; Chavan R; Friedland HD; Bhatia A
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses.
    Wach A; Dembowsky K; Dale GE
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.
    Preston RA; Mamikonyan G; DeGraff S; Chiou J; Kemper CJ; Xu A; Mastim M; Yeole R; Chavan R; Patel A; Friedland HD; Bhatia A
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murepavadin: a new antibiotic class in the pipeline.
    Martin-Loeches I; Dale GE; Torres A
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):259-268. PubMed ID: 29451043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
    Johnson FK; Mudd PN; DiMino T; Vosk J; Sitaraman S; Boudes P; France N; Barlow C
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):256-61. PubMed ID: 27136905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models.
    Melchers MJ; Teague J; Warn P; Hansen J; Bernardini F; Wach A; Obrecht D; Dale GE; Mouton JW
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
    Chang M; Yu Z; Shenker A; Wang J; Pursley J; Byon W; Boyd RA; LaCreta F; Frost CE
    J Clin Pharmacol; 2016 May; 56(5):637-45. PubMed ID: 26358690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
    Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
    Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
    J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
    Tayo B; Taylor L; Sahebkar F; Morrison G
    Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
    Marbury TC; Flint A; Jacobsen JB; Derving Karsbøl J; Lasseter K
    Clin Pharmacokinet; 2017 Nov; 56(11):1381-1390. PubMed ID: 28349386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
    Gretler DD; Guerciolini R; Williams PJ
    Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function.
    Haroldsen PE; Sisic Z; Datt J; Musson DG; Ingenito G
    Clin Ther; 2017 Jul; 39(7):1360-1370. PubMed ID: 28641995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.